Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Unternehmen & Branche
| Name | Pharvaris N.V. |
|---|---|
| Ticker | PHVS |
| CIK | 0001830487 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,94 Mrd. USD |
| Beta | -2,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -100 | 30.03 | -3,003.00 | -2,3% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30.03 | -3,003.00 | -2,3% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30.03 | -3,003.00 | -2,3% | |
| 2026-04-23 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -100 | 30.03 | -3,003.00 | -2,3% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -500 | 30.00 | -15,000.00 | -11,4% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7,000 | 30.05 | -210,361.90 | -159,6% | |
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -7,000 | 30.05 | -210,378.70 | -159,6% | |
| 2026-04-22 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -7,001 | 30.05 | -210,401.75 | -159,7% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7,000 | 30.05 | -210,357.70 | -159,6% | |
| 2026-04-16 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2,292 | 28.60 | -65,558.53 | -49,7% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 28.42 | -5,683.00 | -4,3% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -23,133 | 27.74 | -641,598.38 | -486,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.